|
1
|
Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.
|
J Nucl Med
|
2012
|
1.22
|
|
2
|
Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand.
|
J Neurochem
|
2010
|
1.02
|
|
3
|
In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass.
|
Nucl Med Biol
|
2010
|
1.01
|
|
4
|
Relationship between flow-metabolism uncoupling and evolving axonal injury after experimental traumatic brain injury.
|
J Cereb Blood Flow Metab
|
2004
|
0.94
|
|
5
|
D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics.
|
Hear Res
|
2002
|
0.92
|
|
6
|
Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET.
|
EJNMMI Res
|
2011
|
0.82
|
|
7
|
Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.78
|
|
8
|
Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as ¹⁸F-PET imaging agents for β-amyloid plaques.
|
Bioorg Med Chem Lett
|
2012
|
0.77
|
|
9
|
Synthesis, radiolabeling, and in vivo pharmacokinetic evaluation of the amyloid beta radioligand [11C]AZD4694 in nonhuman primates.
|
Mol Imaging Biol
|
2014
|
0.75
|